Trial Profile

Phase 1/2 study of HUB-101

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HUB 101 (Primary)
Indications Leber congenital amaurosis
Focus Therapeutic Use

Most Recent Events

25 Mar 2025 According to a Hubble Therapeutics media release, the company expects to enter the clinic to conduct Phase I / II trials in 2026 to demonstrate the safety and efficacy of HUB-101.
16 Oct 2024 New trial record
09 Oct 2024 According to an Andelyn Biosciences, Inc media release, HUB-101 has received Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA for this program.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com